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Abstract
There are a number of limitations to using
conventional diagnostic markers for patients with
clinical suspicion of infection. As a consequence,
unnecessary and prolonged exposure to antimicrobial
agents adversely affect patient outcomes, while
inappropriate antibiotic therapy increases antibiotic
resistance. A growing body of evidence supports the
use of procalcitonin (PCT) to improve diagnosis of
bacterial infections and to guide antibiotic therapy.
For patients with upper and lower respiratory tract
infection, post-operative infections and for severe
sepsis patients in the intensive care unit, randomized-
controlled trials have shown a benefit of using PCT
algorithms to guide decisions about initiation and/or
discontinuation of antibiotic therapy. For some other
types of infections, observational studies have shown
promising first results, but further intervention studies
are needed before use of PCT in clinical routine can
be recommended. The aim of this review is to
summarize the current evidence for PCT in different
infections and clinical settings, and discuss the
reliability of this marker when used with validated
diagnostic algorithms.
Background
Emerging bacterial resistance to antimicrobial therapeu-
tics calls for more stringent efforts to reduce antibiotic
overuse [1]. Towards this aim, there has been consider-
able interest in antibiotic stewardship programs aimed
at reducing antibiotic overu s eb yt a i l o r i n ga n t i b i o t i c
therapy to individual needs of patients [2,3]. Despite the
successful implementation of diagnostic biomarkers in
different fields of medicine (for example, D-dimers in
pulmonary embolism, natriuretic peptides in acute heart
failure, troponin in myocardial infarction), accurate and
timely diagnosis of bacterial infections remains a chal-
lenge [4,5]. Reliable clinical and/or microbiological para-
meters from easy to obtain specimens that may be used
to diagnose bacterial infections and rule out other infec-
tions not in need of antibiotic therapy have been largely
lacking. The main disadvantages of many current micro-
biological methods are diagnostic delays (for example,
culture methods), suboptimal sensitivity (for example,
blood cultures) and low specificity due to contamination
(for example, sputum cultures), whereas others are not
amenable to routine diagnostics due to their invasive
nature (for example, lung biopsy). Inflammatory mar-
kers, such as C-reactive protein (CRP) or white blood
cells (WBC), lack specificity for bacterial infections [6].
This is partly explained by the heterogeneity of different
infections and the complex interaction of different pro-
and anti-inflammatory mediators of the host response
aimed at combating invading pathogens during systemic
infections, which depend on timing, type, extent and
site of the underlying infection.
In this diagnostic dilemma, procalcitonin (PCT) has
stimulated great interest as a potentially more specific
marker for bacterial infection. PCT is produced ubiqui-
tously in response to endotoxin or mediators released in
response to bacterial infections (that is, interleukin (IL)-
1b, tumor necrosis factor (TNF)-a, and IL-6) and
strongly correlates with extent and severity of bacterial
infections [7]. Because up-regulation of PCT is attenu-
ated by interferon (INF)-g, a cytokine released in
response to viral infections, PCT is more specific for
bacterial infections and may help to distinguish bacterial
infections from viral illnesses [8-11]. PCT shows a favor-
able kinetic profile for use as a clinical marker: it
promptly increases within 6 to 12 hours upon stimula-
tion and circulating PCT levels halve daily when the
infection is controlled by the host immune system or
antibiotic therapy [12]. PCT correlates with bacterial
load [13-15] and severity of infection [6,16-18]. PCT
thus has prognostic implications and the course of PCT
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acquired pneumonia (CAP) [18-21] and critically ill
patients with sepsis [22].
Based on this evidence, PCT has been put forward as
a promising candidate marker for diagnosis and for anti-
biotic stewardship in patients with systemic infections
[ 2 3 ] .I m p o r t a n t l y ,a sw i t ha n yd i a g n o s t i ct o o l ,P C T
should be used embedded in clinical algorithms adapted
to the type of infection and the clinical context and set-
ting. While for some types of infections and clinical set-
tings optimal PCT cut-offs have been established and
their safety and efficacy shown in randomized-controlled
intervention trials, for other types of infection only
observational studies are available today (Figure 1), and
thus the clinical benefit and safety of using PCT remains
undefined.
The aim of this review is to summarize the current
evidence for PCT in different infections and clinical set-
tings, and discuss the strengths and limitations of PCT,
and the reliability of this marker when used with vali-
dated diagnostic algorithms.
Procalcitonin as a diagnostic marker: results from
observational studies
A plethora of observational studies have investigated the
diagnostic potential of PCT in different clinical situa-
tions and different types and sites of infections. Table 1
summarizes study designs, proposed PCT cut-offs and
main conclusions of selected relevant studies investigat-
ing different types of infections. This selection focuses
on more recent research and on studies using highly
sensitive PCT assays (that is, with a functional assay
sensitivity around 0.06 μg/L) [24,25].
For the diagnosis of blood stream infections and bac-
teremia, studies found a high diagnostic performance of
PCT [13-15]. To distinguish blood contamination from
true blood stream infection in patients with growth of
coagulase-negative staphylococci in their blood cultures,
Figure 1 Available evidence concerning PCT in different infections derived from observational and randomized-controlled
intervention studies. While for some infections, intervention studies have investigated benefit and harm of using PCT for antibiotic decisions
(right side), for other infections only results from diagnostic (observation) studies are available with mixed results (left side). Abbreviations: PCT,
procalcitonin. + moderate evidence in favor of PCT; ++ good evidence in favor of PCT; +++ strong evidence in favor of PCT; ? evidence in favor
or against the use of PCT still undefined
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pared to WBC and CRP [13]. At a cut-off of 0.1 ug/L,
PCT had a very high sensitivity to exclude true infec-
tion. Two other studies, focused on the use of PCT to
predict bacteremia infections in patients with CAP [14]
and urinary tract infections (UTI) [15]. A PCT cut off of
0.25 ug/L was most helpful to exclude bacteremic dis-
ease with a high negative predictive value in both
settings.
In UTIs, evidence for the utility of PCT comes pri-
marily from the pediatric literature, where it has a simi-
lar sensitivity but superior specificity compared to CRP
for the prediction of pyelonephritis in children with feb-
rile UTIs [26]. It correlates with the extent of renal
involvement and with renal scarring. Similarly, in
patients with infectious endocarditis, circulating PCT
levels were elevated compared to non-infected patients
in two independent studies [27,28]. Unfortunately, a reli-
able PCT threshold for diagnosing or excluding infective
endocarditis was neither proposed nor tested in inter-
vention studies. Importantly, subacute forms of endocar-
ditis or prosthetic-valve endocarditis may show different
characteristics compared to acute forms due to their
low inflammatory nature and possibly biofilm
production.
Few studies have investigated the use of PCT in intra-
abdominal infections [29-36]. While PCT showed pro-
mise as a marker to exclude perforation and ischemia in
obstructive bowel syndrome [32], the utility in acute
appendicitis [31] and pancreatitis [33,36] was limited
and PCT was more helpful as a prognostic marker for
severe disease and adverse outcome. While localized
infections may not induce a massive PCT up-regulation,
studies found PCT of diagnostic utility in patients with
Table 1 Overview of studies investigating the use of PCT in different types and sites of infection
Type of infection Study
designs
PCT cut-off
(ug/L)
Benefit of
using PCT?
Main conclusions Selected
References
Abdominal Infections observational 0.25 ? PCT may help to exclude ischemia and necrosis in bowel
obstruction
[29-32]
Arthritis observational 0.1-0.25 + PCT differentiates non-infectious (gout) arthritis from true
infection
[37,38,73]
Bacteremic infections observational 0.25 ++ Low PCT levels help to rule out bacteremic infections [14,15,74]
Blood stream infection
(primary)
observational 0.1 ++ PCT differentiates contamination from true infection [13]
Bronchitis RCT 0.1-0. 5 +++ PCT reduces antibiotic exposure in the ED without adverse
outcomes
[50,52]
COPD exacerbation RCT 0.1-0. 5 +++ PCT reduces antibiotic exposure in the ED and hospital
without adverse outcomes
[50-52]
Endocarditis observational 2.3 + PCT is an independent predictor for acute endocarditis
with high diagnostic accuracy
[27,28]
Meningitis before-after 0.5 + PCT reduces antibiotic exposure during outbreak of viral
meningitis
[75-77]
Neutropenia observational 0.1-0.5 + PCT is helpful at identifying neutropenic patients with
systemic bacterial infection
[39-41]
Pancreatitis observational 0.25-0.5 ? PCT correlates with severity and extend of infected
pancreatitis
[33,36]
Pneumonia RCT 0.1-0. 5; 80-
90% ↓
+++ PCT reduces antibiotic exposure in the hospital without
adverse outcomes
[16,50,52-55]
Postoperative fever observational 0.1-0.5 + PCT differentiates non-infectious fever from post-operative
infections
[78]
Postoperative
Infections
RCT 0.5-1.0; 75-
85% ↓
++ PCT reduces antibiotic exposure in the surgical ICU without
adverse outcomes
[64,65]
Severe sepsis/Shock RCT 0.25-0.5; 80-
90% ↓
+++ PCT reduces antibiotic exposure in the ICU without adverse
outcomes
[61,62]
Upper respiratory tract
infections
RCT 0.1-0.25 ++ PCT reduces antibiotic exposure in primary care without
adverse outcomes
[58]
Urinary tract infections observational 0.25 + PCT correlates with severity of urinary tract infections [15,26]
Ventilator-associated
pneumonia
RCT 0.1-0.25 ++ PCT reduces antibiotic exposure without adverse outcomes [62,63]
Abbreviations: COPD, chronic obstructive pulmonary disease; ED, Emergency department; PCT, procalcitonin; RCT, randomized-controlled trial. The level of
evidence in favor or against PCT for each infection was rated by two of the coauthors (PS, WCA) independently and disagreements were resolved by consensus.
+ moderate evidence in favor of PCT; ++ good evidence in favor of PCT; +++ strong evidence in favor of PCT; ? evidence in favor or against the use of PCT still
undefined
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Page 3 of 9arthritis [37] and osteomyelitis [38], particularly when
subtle increases and a low PCT cut off (0.1 ug/L) were
considered.
Different studies have evaluated the utility of PCT in
patients with febrile neutropenia [39-41]. A recent sys-
tematic review found 30 articles on the topic and con-
cluded that PCT has value as a diagnostic and
prognostic tool in patients with febrile neutropenia, but
that due to differences in patient populations and study
qualities, further research is needed [40]. Importantly in
this regard, the production of PCT seems not to be atte-
nuated by corticosteroids [42,43] and PCT production
does not rely on white blood cells [44-46]. A study
including 102 critically ill patients with systemic infec-
tions in a medical intensive care unit (ICU) found signif-
icantly lower CRP and IL-6 levels, but similar PCT
levels, in patients treated with systemic corticosteroids
(20 to 1500 mg/day of prednisone parenterally) com-
pared to untreated patients[42]. These observations
were confirmed in healthy male volunteers who received
different doses of prednisolone up to 30 mg before a
sepsis-like syndrome was induced with Escherichia coli
lipopolysaccharide (LPS) injections[43]. While other bio-
markers were significantly inhibited in a dose-dependent
way, levels of PCT showed no inhibition within the
study period. Whether this is also true for other corti-
costeroid doses, however, remains unknown. The value
of PCT in febrile neutropenia may be as part of a com-
bination with other biomarkers of bacterial infection
such as IL-6 and IL-8 as shown in a small study of
pediatric patients with febrile neutropenia [39].
Procalcitonin as a guide for antibiotic decisions:
results from randomized-controlled studies
The clinical implications of the above mentioned obser-
vational studies may be limited by differences in disease
definitions and patient groups, use of insensitive (semi-
quantitative) PCT assays, and different methodological
issues such as observer bias, selection bias and issues of
sample availability, co-infection and colonization. To
overcome these limitations, several randomized-con-
trolled studies have investigated the use of PCT to assist
in decisions about initiation and/or duration of antibio-
tic therapy (antibiotic stewardship). Thereby the benefit
of PCT was measured by clinical outcomes, assuming
that if the patient recovers without antibiotics, there was
no relevant bacterial illness in need of antibiotic therapy.
Importantly, all intervention studies used fully auto-
mated highly sensitive PCT assays, the results of which
can be obtained in the clinical routine of an emergency
department within one hour thus permitting bed-side
decision making. Recently, different options for PCT
testing have become available, including the KRYPTOR
[25], the VIDAS system (Biomerieux) [47], the Liaison
BRAHMS PCT (DiaSorin)[48] and the Elecsys BRAHMS
PCT (Roche Diagnostics) [49].
All published studies on antibiotic stewardship used
similar clinical algorithms with recommendations for or
against antibiotic treatment based on PCT cut-off
ranges. For moderate risk patients with respiratory tract
infections in the emergency department (Figure 2), algo-
rithms recommended initiation and discontinuation of
antibiotic therapy based on four different cut-off ranges.
Initial antibiotics were withheld mostly in patients with
low risk for systemic infection with acute bronchitis or
exacerbation of chronic obstructive pulmonary disease
[ECOPD]). Clinical re-evaluation and a repeated mea-
surement of PCT were recommended after 6 to 24
hours if the clinical condition did not improve sponta-
neously. If PCT values were increased and antibiotic
therapy was initiated, repeated PCT measurements were
recommended every one to two days, depending on the
clinical severity of disease, and antibiotics were discon-
tinued using the same cut off ranges or a marked drop
by 80% to 90% if initial levels were high (for example >5
μg/l). To assure safety, specific criteria were predefined
where this algorithm could be overruled, such as life-
threatening disease or immediate need for ICU admis-
sion. For high risk patients in the ICU setting (Figure 3),
algorithms focused on discontinuation of antibiotic ther-
apy if a patient showed a clinical recovery and PCT
levels decreased to ‘normal’ levels, or by at least 80% to
90%.
The first intervention study testing PCT as a guide for
antibiotic decisions included patients with different
types and severities of respiratory infections [50]. Clini-
cal outcomes for both groups were similar, but the
PCT-guided group had markedly lower rates of antibio-
tic prescriptions (44% versus 83%), particularly in
patients with ECOPD and acute bronchitis. Two subse-
quent trials evaluated the effect of PCT guidance for
antibiotic discontinuation in CAP and ECOPD. PCT
guidance reduced the duration of antibiotic therapy by
65% in CAP patients [16] and the prescription of anti-
biotics from 72% to 40% in ECOPD patients [51]. A
subsequent multicenter trial [52] confirmed earlier
results and found a reduction of antibiotics by 32% in
CAP, by 50% in ECOPD and by 65% in acute bronchitis.
Again, antibiotic exposure in ECOPD and acute bron-
chitis decreased mainly by not initiating treatment at all,
whereas for CAP it was principally from reduction in
duration of therapy. Importantly, the overall rate of
adverse events was similar in both study arms and
excluded a risk of more than 0.4% for PCT guided
patients. Interestingly, patients with bacteremia CAP
had markedly increased PCT concentrations resulting in
longer treatment duration compared to culture-negative
CAP patients with a lower infection-related risk [17].
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Page 4 of 9Figure 2 PCT algorithm in patients with respiratory tract infections in the Emergency Department. The clinical algorithm for antibiotic
stewardship in patients with respiratory tract infections in the Emergency Department encourages (>0.5 μg/l or >0.25 μg/l) or discourages (<0.1
μg/l or <0.25 μg/l) initiation or continuation of antibiotic therapy more or less based on PCT specific cut-off ranges. Abbreviations: AB, antibiotic;
LRTI, lower respiratory tract infection; PCT, procalcitonin; PSI, Pneumonia Severity Score.
Figure 3 PCT algorithm in patients with sepsis in the ICU. In critically ill patients in the ICU, cut-offs are higher and initial empiric antibiotic
therapy should be encouraged in all patients with suspicion of sepsis. PCT cut-offs are helpful in the subsequent days after admission to shorten
the courses of antibiotic therapy in patients with clinical improvement. Abbreviations: AB, antibiotic; PCT, procalcitonin.
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were also reported in trials from Denmark [53] and
China [54,55], and recently from an observational ‘real
life’- quality control survey in Switzerland [56].
Arguably, the most important (over-) use of antibiotics
occurs in primary care. As many as 75% of patients with
upper and lower respiratory infections receive antibio-
tics, despite the mostly viral origin of the condition [57].
Two multicenter primary care trials, powered for non-
inferiority of clinical outcomes, investigated the safety
and feasibility of PCT guided algorithms in patients with
upper and lower respiratory infections, essentially rely-
ing on an initial PCT measurement only [58-60]. Both
trials found substantial reductions in antibiotic exposure
(by 75% and 42%), and similar clinical outcomes, parti-
cularly a similar time to recovery.
In more high risk patients in the ICU setting, different
trials have investigated the use of PCT, mainly for dis-
continuation of antibiotics. The first small proof of con-
cept study [61] found a four-day reduction in the
duration of antibiotic therapy in patients with severe
sepsis, but only in the per protocol analysis. A subse-
quent large multicenter trial in France recently validated
this concept in more than 600 patients [62]. PCT guided
patients had similar 30-day mortality rates and similar
rates of relapses, but markedly more antibiotic-free days
alive (14.3 versus 11.6). Another multinational ICU
study focused on ventilator-associated pneumonia and
found that PCT guidance resulted in a higher number
of antibiotic free-days alive (13 versus 9.5 days) [63].
Two German studies assessed the effect of PCT gui-
dance in surgical ICU patients with suspected bacterial
infections in the post-operative course [64,65]. PCT gui-
dance resulted in a significant reduction of antibiotic
therapy and similar medical outcomes. In addition, the
length of intensive care treatment in the PCT-guided
group was significantly shorter than that in the control
group (15.5 versus 17.7 days), a finding similar to the
first ICU study [61]. Importantly, the use of PCT for
discontinuation of antibiotics in ICU patients is still lim-
ited by a relatively small number of patients included in
previous trials and awaits further large-scale validation.
There are currently different ongoing trials focusing on
this vulnerable patient population that should shed
further light on the benefits and harms of PCT use in
ICU patients.
Limitations and areas of uncertainty
Sepsis is not a well-defined disease, but a consequence
of different infectious disease entities and far too com-
plex to be reduced to a single cut-off of any surrogate
marker. Limitations of every PCT measurement include
false-positive and false-negative results [8,11]. Different
pathogens might induce distinct responses resulting in a
variable up-regulation of circulating PCT levels [66].
While highly elevated PCT levels were found in patients
with pneumococcal CAP [14], the same was not true in
CAP due to atypical organisms such as mycoplasma
[66]. Antimicrobial pre-treatment may influence the
level of PCT resulting in lower PCT levels [67], although
it remains unclear whether this relates to a direct effect
or rather to lower microbial burden in patients treated
with antibiotics. Unspecific elevations of PCT levels in
the absence of a bacterial infection can typically be seen
in situations of massive stress, for example after severe
trauma and surgery [8,68-70] or in patients after cardiac
shock [71]. Although the available evidence from inter-
vention studies favors the use of PCT for de-escalation
of antibiotic therapy, the same may not be true for esca-
lation of antibiotics when PCT increases as recently
demonstrated [72]. In this study PCT-guided escalation
of diagnostic procedures and antibiotic therapy in the
ICU did not improve survival and led to worse second-
ary outcomes in patients.
Summary, future directions and conclusions
For upper and lower respiratory tract infection in ICU
patients with sepsis and post-operative infections, rando-
m i z e d - c o n t r o l l e ds t u d i e sh a v es h o w nt h ee f f i c a c yo f
using PCT algorithms to guide antibiotic decisions. For
other types of infections, only observational studies are
available which are importantly limited by the lack of a
true gold standard. Most intervention studies were con-
ducted in European countries including Switzerland,
Germany, France and Denmark (and two in China) and
validation in other countries and continents is therefore
warranted. Importantly, PCT levels must always be eval-
uated in the context of a careful clinical and microbiolo-
gical assessment. As the kinetics of PCT are of
particular diagnostic and prognostic interest, repeated
measurements should be performed if feasible, especially
in persistently sick patients if antibiotics are withheld.
The limitations of every PCT measurement include
false-positive and false-negative results [8]. Unspecific
elevations of PCT levels in the absence of a bacterial
infection can typically be seen in situations of massive
cell death, for example after severe trauma or surgery
[8,68,69]. In these situations, PCT values are usually
only moderately elevated and show a rapid decline in
follow-up measurements. Conversely, falsely low PCT
levels, typically seen during the early course or localized
state of an infection, often show an increase in the fol-
low-up measurements. Therefore, highly sensitive PCT
assays are required, as subtle changes of PCT at very
low concentrations can be monitored, increasing the
sensitivity of the test and thus the safety of patients.
Emerging bacterial resistance to antimicrobial agents
calls for more effective efforts to reduce the unnecessary
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bacterial and resolving diseas e s[ 1 ] .P a t i e n t sa n dp h y s i -
cians share a common goal of improving symptoms
from infection as fast as possible and often see antibio-
tics as the most expeditious intervention to achieve it.
This one-size fits-all approach fails to consider the basic
questions of who benefits from antibiotic therapy, and if
treated, what would be the optimal duration. Using
PCT, which mirrors the likelihood of bacterial infection
and the severity of infection, to guide antibiotic therapy,
is a persuasive, evidence-based approach to a more
rational use of antibiotics.
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